TANDEM DIABETES CARE INC (TNDM)
Health Care · Medical devices (diabetes care) · NASDAQ
Tandem Diabetes Care provides advanced, consumer-focused automated insulin delivery systems designed to simplify diabetes management.
What TANDEM DIABETES CARE INC does
Tandem Diabetes Care is a medical technology company that designs, develops, and commercializes advanced insulin delivery systems for individuals living with diabetes. Its core product portfolio includes automated insulin delivery (AID) pumps, such as the t:slim X2 and the Tandem Mobi, which integrate hybrid closed-loop control technology. The company serves nearly 500,000 users across more than 25 countries.
Themes: diabetes technology, insulin delivery systems, automated insulin delivery (AID), hybrid closed-loop technology
Fundamentals
- Price$16.52 as of 2026-10-20 close
- Market cap$1.1B as of 2026-08-03 (share count; price 2026-10-20)
- 1-year return+6.3% 2025-10-20 close $15.54 → 2026-10-20 close $16.52
- P/En/a negative earnings
- Net margin-20.2% FY2025, SEC XBRL
- Gross margin+53.8% FY2025, SEC XBRL
- ROE-131.9% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity4.62 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+7.9% FY2025, SEC XBRL
- Revenue CAGR (3y)+8.2% SEC XBRL
- Beta1.12 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How TNDM compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $255M | $145M | -$14M | -$21M | -$0.31 | -$35M† | $4M† |
| Q1 FY2026 2026-03-31 | $247M | $137M | -$17M | -$20M | -$0.30 | $11M | $6M |
| Q4 FY2025 2025-12-31 | $290M | $167M | $8M | -$589000 | -$0.01 | $10M† | $7M† |
| Q3 FY2025 2025-09-30 | $249M | $134M | -$23M | -$21M | -$0.31 | $8M† | $4M† |
| Q2 FY2025 2025-06-30 | $241M | $126M | -$52M | -$52M | -$0.78 | -$9M† | $6M† |
| Q1 FY2025 2025-03-31 | $234M | $118M | -$121M | -$131M | -$1.97 | -$18M | $3M |
| Q4 FY2024 2024-12-31 | $283M | $157M | -$581000 | $755000 | $0.01 | $11M† | $3M† |
| Q3 FY2024 2024-09-30 | $244M | $125M | -$26M | -$23M | -$0.35 | $27M† | $5M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$63M
- Short-term investments$393M
- Total debt$603M borrowings only; leases excluded
- Net debt$147M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How TANDEM DIABETES CARE INC looks technically
TANDEM DIABETES CARE INC (TNDM) is trading 13.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 8 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 19 trading days ago. It is 44.3% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 13.6% below its 200-day average, the long-term trend line — a long-term downtrend | -13.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $18.76 | $18.76 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $19.13 | $19.13 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 15.125. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 8 trading days ago — a "death cross", a bearish long-term signal | 8 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30) | 46.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($15.13 to $17.35) — its "stochastic" reading is 63 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 62.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $29.65 | $29.65 |
|---|---|---|
| From the 52-week high | it is 44.3% below its 52-week high (its highest price of the past year) | -44.3% |
| Above the 52-week low | it is 34.7% above its 52-week low (its lowest price of the past year) | +34.8% |
| Below the 52-week high | it is 44.3% below its highest point of the past year | 44.3% |
| Since a 20-day breakout | it made a new 20-day low about 19 trading days ago | 19 sessions |
| Since a 55-day breakout | it made a new 55-day high about 45 trading days ago | 45 sessions |
| All-time high | its highest closing price on record is $302.50 (set on 2014-01-14) | $302.50 |
| Given back of the 52-week move | over the past year its closes ranged ($12.82 to $28.26), and it has recovered roughly a quarter of its fall from last year’s high — 24% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $22.36 to $22.86. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 24.0% |
| From the all-time high | it is 94.5% below its all-time high | -94.5% |
| Nearest price level | it is trading 0.6% above a support level at $16.42 — a price it turned at twice since 2025-04-30, most recently on 2026-06-26. Since 2024-10-21 it has 5 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.6% |
| All-time low | its lowest closing price on record is $2.14 (set on 2018-02-09) | $2.14 |
| Above the all-time low | it is 672.0% above its all-time low | +672.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9334 between its high and its low — about 5.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9334 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $15.51 and $16.96 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $15.51 – $16.23 – $16.96 |
| Typical daily range (% of price) | its price moves about 5.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.7% |
| Stretch from the 200-day average | it is trading 2.8 daily ranges below its 200-day average price (13.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.71× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.3% since the prior reading | -0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.04 toward sell |
Candlestick patterns
2
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Gap filled | a 2.2% gap down opened on 2026-10-07 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +1.72% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.0 percentage points (the stock lost 2.1% while the market gained 1.0%) | -3.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 12.4 percentage points (the stock lost 8.7% while the market gained 3.6%) | -12.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 30.7 percentage points (the stock lost 22.2% while the market gained 8.5%) | -30.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 8.3 percentage points (the stock gained 6.3% while the market gained 14.6%) | -8.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 16% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.1% of the share price. | -16.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $19.18 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | -13.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 11% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $18.61 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | -11.2% |
Price levels it has turned at before
TNDM last closed at $16.52 on 2026-10-20. Since 2024-10-21 it has turned at 5 prices below its last close and 12 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $16.42 | Support | 0.6% below the last close | turned there twice · 2025-04-30 to 2026-06-26 |
| $15.94 | Support | 3.5% below the last close | turned there twice · 2025-04-21 to 2025-10-21 |
| $17.20 | Resistance | 4.1% above the last close | turned there three times · 2025-07-29 to 2026-10-02 |
| $15.66 | Support | 5.2% below the last close | turned there twice · 2025-04-07 to 2025-10-09 |
| $17.64 | Resistance | 6.8% above the last close | turned there three times · 2025-03-10 to 2026-04-29 |
| $18.09 | Resistance | 9.5% above the last close | turned there three times · 2026-04-02 to 2026-09-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $15.13.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 4 trading days, since 2026-10-15.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.04 mean, 1=Strong Buy…5=Strong Sell) — 21 analysts
- Mean price target$27.76 range $18.00 – $50.00; median $26.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TNDM
- Consensus EPS estimate-$0.2402 next reporting period, as of 2026-10-20
- Estimate change, 30 days+$0.00206 from -$0.2423, on 2026-09-15, 35-day window
- Readings revised upward10% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a limited number of contract manufacturers and suppliers for critical components.","Potential for rapid technological changes and evolving competitive landscape in diabetes management.","Sensitivity to regulatory approvals and evolving cybersecurity threats."]
What changed in the latest 10-Q
AI-assisted comparison of TNDM's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) adds: 'cybersecurity threats, macroeconomic pressures or uncertainties' to the list of forward-looking statement topics in the risk disclosure section
- Newer filing (2026-05-07) adds: 'We serve nearly 500,000 people living with diabetes in more than 25 countries worldwide' in the Overview section
- Newer filing (2026-05-07) adds: description of Android control for Mobi 'followed by Android control in March 2026'
- Newer filing (2026-05-07) adds: 'Control-IQ+ launched in 2025 and is our third and newest AID algorithm, which is available globally and indicated for people ages 2+ (type 1)'
- Newer filing (2026-05-07) adds: 'In the United States, it is also indicated for use in pregnancy complicated by type 1 diabetes as well as people 18+ living with type 2 diabetes'
- Newer filing (2026-05-07) adds: 'It is the only predictive algorithm featuring AutoBolus corrective bolusing'
- Newer filing (2026-05-07) adds: 'Control-IQ+ also offers an easy set-up feature and settings for sleep and exercise activities that adjust the algorithm parameters to better match the different physiological needs during these activities'
- Newer filing (2026-05-07) adds: 'in the first quarter of 2026 we offered users the choice of integrating with multiple CGM sensors, such as such as the Dexcom G6 and G7, and the Abbott FreeStyle Libre 2 Plus and FreeStyle Libre 3 Plus'
- Removed:
- Older filing (2025-11-06) states: 'except to the extent required by law or the rules of the Nasdaq Global Market' in forward-looking statement disclaimer – removed in newer filing (2026-05-07)
- Older filing (2025-11-06) describes: 'We are a global insulin delivery and diabetes technology company focused on the design, development and commercialization of technology solutions' – replaced with 'Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology' in newer filing (2026-05-07)
- Older filing (2025-11-06) states: 'We consider our primary addressable market to be people who live with type 1 diabetes, and we expanded our U.S. addressable market this year to include people living with type 2 diabetes who require intensive insulin therapy' – removed in newer filing (2026-05-07)
- Older filing (2025-11-06) states: 'We sell to customers in approximately 25 countries worldwide, and the majority of our sales come from customers in the United States' – removed in newer filing (2026-05-07)
- Older filing (2025-11-06) describes Mobi as 'the world's smallest durable automated insulin delivery (AID) system. At approximately half the size of our t:slim X2 pump' – removed in newer filing (2026-05-07)
- Older filing (2025-11-06) states: 'In the first half of 2024, we scaled the commercial release of Tandem Mobi in the United States' – removed in newer filing (2026-05-07)
- Older filing (2025-11-06) states: 'In May 2025, we received CE Mark approval for the Tandem Mobi insulin delivery system with Control-IQ+ technology. We are pursuing additional regulatory and pre-commercial activities, such as securing in-country registrations and reimbursement, before launching Tandem Mobi outside the United States' – removed in newer filing (2026-05-07)
- Older filing (2025-11-06) describes Control-IQ+ as 'an advanced hybrid-closed loop feature' – language changed in newer filing (2026-05-07)
- Reworded:
- Newer filing (2026-05-07) changes description of company strategy from 'by offering flexibility and choice in intelligent insulin delivery systems, through an accessible portfolio of market-leading pumps, applications, and insights' to 'to offer flexibility and choice in intelligent insulin delivery systems through an accessible portfolio of market-leading pumps, applications and insights'
- Newer filing (2026-05-07) adds 'Tandem pump platforms include' before listing t:slim X2 and Mobi, whereas older filing (2025-11-06) stated 'our portfolio includes both the t:slim X2 and Tandem Mobi insulin pumps'
- Newer filing (2026-05-07) changes product launch description from 'We launched our flagship t:slim pump platform in August 2012, and its next generation, the t:slim X2, in October 2016' – language not present in older filing's Overview section structure
- Newer filing (2026-05-07) describes Control-IQ+ as 'hybrid closed loop algorithm' versus older filing (2025-11-06) describing it as 'advanced hybrid-closed loop feature'
- Newer filing (2026-05-07) states CGM integration allows 'insulin pump to receive CGM sensor readings, which can then be used in our Control-IQ+ technology' versus older filing describing it could be used 'in our AID algorithms, including our Control-IQ+ technology'
- Notes:
- Text in newer filing appears truncated at the end of the Overview section ('Tandem Source also provides us with data that we can analyze to reveal patterns, trends, outcomes and associations that can be used for product dev'), making full comparison of remaining content not possible
- Older filing's Overview section continues beyond the excerpted text ('For more than a decade we have offered our customers...'), so full scope of Overview changes may not be fully captured
Risk Factors
- Added:
- New risk factor added (filed 2026-05-07): 'We are implementing a multi-channel managed care strategy in the United States that impacts the pricing model for our pumps and our supplies sold through the pharmacy channel. If our pharmacy channel strategy fails to achieve its intended outcome, our growth, business, results of operations, and financial condition could be materially and adversely impacted.'
- New risk factor added (filed 2026-05-07): 'Failure to obtain any required regulatory authorization, clearance or certification in foreign jurisdictions will prevent us from marketing our products in international markets.'
- New risk factor added (filed 2026-05-07): 'Servicing the Notes will require a significant amount of cash, and we may not have sufficient cash flow from our business to repay the Notes.' (appears under Risks Related to Our Indebtedness)
- New risk factor added (filed 2026-05-07): 'New products or modifications to our existing products may require new 510(k) clearances, PMAs, CE Marks or other certifications, or may require us to cease marketing or recall the modified products until clearances, certifications or approvals are obtained.'
- New risk factor added (filed 2026-05-07): 'The price of our common stock may continue to fluctuate significantly.'
- Removed:
- Risk factor removed (filed 2025-11-06): 'We operate in a very competitive industry and if we fail to compete successfully against our existing or future competitors, or if the competitive environment harms our business partners, our financial condition and operating results may be negatively affected.'
- Risk factor removed (filed 2025-11-06): 'We may face unexpected challenges in marketing and selling our products, and training new customers on the use of our products, which could harm our ability to achieve our sales forecasts.'
- Risk factor removed (filed 2025-11-06): 'We have incurred a significant amount of indebtedness and the agreements governing such indebtedness subject us to required debt service payments, any of which may restrict our financial flexibility and affect our ability to operate our business.' (from Risks Related to Our Indebtedness)
- Risk factor removed (filed 2025-11-06): 'International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, and operating results.'
- Risk factor removed (filed 2025-11-06): 'We may be subject to damages resulting from claims that we, or our employees, have wrongfully used or disclosed trade secrets or other proprietary information of our competitors.' (appears to be missing from newer filing)
- Reworded:
- Changed (filed 2025-11-06 to 2026-05-07): 'We currently rely on sales of insulin pump products to generate a significant portion of our revenue' changed to 'We currently rely on sales of insulin pump products to generate a significant portion of our sales'
- Changed (filed 2025-11-06 to 2026-05-07): 'Our ability to maintain and grow our revenue depends' changed to 'Our ability to maintain and grow our sales depends'
- Changed (filed 2025-11-06 to 2026-05-07): 'Our sales and marketing efforts in the United States are largely dependent on independent distributors' changed to 'Our sales and marketing efforts depend on independent distributors' (geographic qualifier 'in the United States' and intensity qualifier 'largely' removed)
- Changed (filed 2025-11-06 to 2026-05-07): 'the failure to successfully complete clinical trials and studies' changed to 'the failure to successfully complete those trials and studies'
- Changed (filed 2025-11-06 to 2026-05-07): 'Any concerns regarding the safety or efficacy of our products' changed to 'Any concerns regarding the safety and efficacy of our products' (changed 'or' to 'and')
- Changed (filed 2025-11-06 to 2026-05-07): 'Commercializing our products outside of the United States' changed to 'Commercializing our products internationally' (broader geographic framing)
- Changed (filed 2025-11-06 to 2026-05-07): 'We may be subject to stringent and evolving' changed to 'We are subject to stringent and evolving' (changed 'may be' to 'are')
- Changed (filed 2025-11-06 to 2026-05-07): 'loss of revenue or profits; loss of customers or sales' changed to 'loss of sales or profits; loss of customers' (reordered and simplified phrasing)
- Changed (filed 2025-11-06 to 2026-05-07): 'loss of revenue or profits; loss of customers or sales' changed to 'loss of sales or profits; loss of customers' (in second data privacy risk factor as well)
- Changed (filed 2025-11-06 to 2026-05-07): Section title changed from 'Risks Related to Our Future Financings and Financial Results' to 'Risks Related to Our Financial Results and Future Financings' (reordered)
- Changed (filed 2025-11-06 to 2026-05-07): Section title changed from 'Risks Related to Our Indebtedness' standalone to part of restructured section organization
- Notes:
- The newer filing text appears truncated at the end and does not include footnote references or full concluding text that may be present in the complete filing.
- The older filing text is also partially truncated at the very end, cutting off mid-sentence regarding risk factors marked with asterisks.
- Some risk factor removals may represent reorganization or consolidation rather than complete elimination; full text review of complete filings recommended for verification.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for TNDM — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 5 matched disclosures for TNDM from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding TNDM as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 19,119,561
- Reported value $288,514,179
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about TNDM's institutional holders → See what each manager we track holds →
Short interest (FINRA)
TNDM had 13,369,091 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
TNDM had 19.2% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.25 days to cover at the same settlement.
- Reported short interest (shares) 13,369,091
- Short interest (% of shares outstanding) 19.2%
- Prior settlement (shares) 12,474,385
- Reported change 7.17%
- Days to cover (reported) 5.25
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Insulet (PODD)
- Medtronic (MDT)
- Roche (Diabetes Care)
- DexCom (DXCM)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TNDM vs…
Frequently asked questions
What does TANDEM DIABETES CARE INC (TNDM) do?
Tandem Diabetes Care is a medical technology company that designs, develops, and commercializes advanced insulin delivery systems for individuals living with diabetes. Its core product portfolio includes automated insulin delivery (AID) pumps, such as the t:slim X2 and the Tandem Mobi, which integrate hybrid closed-loop control technology. The company serves nearly 500,000 users across more than 25 countries.
What sector is TANDEM DIABETES CARE INC (TNDM) in?
TANDEM DIABETES CARE INC (TNDM) is classified in the Health Care sector. Its industry is Medical devices (diabetes care). It trades on NASDAQ.
Who are TANDEM DIABETES CARE INC's (TNDM) competitors?
Notable peers of TANDEM DIABETES CARE INC (TNDM) include Insulet, Medtronic, Roche (Diabetes Care) and DexCom. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in TNDM?
Yes — we hold 5 matched STOCK Act disclosures for TNDM from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is TANDEM DIABETES CARE INC (TNDM) overbought or oversold right now?
TANDEM DIABETES CARE INC (TNDM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 46, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TNDM come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.